Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Ghrelin - A Possible Opportunity to Improve Appetite (Phase 3)

This study has been completed.
Sponsor:
Collaborators:
Swedish Cancer Foundation
Medical Research Council
Information provided by:
Göteborg University
ClinicalTrials.gov Identifier:
NCT00681486
First received: May 19, 2008
Last updated: August 20, 2009
Last verified: August 2009

May 19, 2008
August 20, 2009
October 2003
June 2008   (final data collection date for primary outcome measure)
Food intake [ Time Frame: June 2008 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00681486 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Ghrelin - A Possible Opportunity to Improve Appetite
Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss

The study is designed to evaluate whether ghrelin treatment can improve appetite in weight losing cancer patients.

Randomized study with follow up evaluations each month until preterminal state. Cancer patients will be randomised to either high dose or low dose of active treatment given as daily injection.

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Cancer
  • Drug: Ghrelin
    High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
  • Drug: Ghrelin
    Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
  • Active Comparator: A, 1
    Ghrelin
    Intervention: Drug: Ghrelin
  • Active Comparator: A, 2
    Ghrelin.
    Intervention: Drug: Ghrelin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
July 2008
June 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Weight loss

Exclusion Criteria:

  • Diabetes
Both
40 Years to 80 Years
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT00681486
kl4501123
Not Provided
Professor Kent Lundholm, University of Gothenburg
Göteborg University
  • Swedish Cancer Foundation
  • Medical Research Council
Principal Investigator: Kent Lundholm, MD, prof Göteborg University
Göteborg University
August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP